Collegium Pharmaceutical Inc (NASDAQ:COLL) – Stock analysts at Jefferies Group lifted their FY2017 EPS estimates for Collegium Pharmaceutical in a report released on Sunday. Jefferies Group analyst D. Steinberg now forecasts that the specialty pharmaceutical company will post earnings per share of ($2.58) for the year, up from their previous estimate of ($2.61). Jefferies Group has a “Buy” rating and a $32.00 price objective on the stock. Jefferies Group also issued estimates for Collegium Pharmaceutical’s Q4 2017 earnings at ($0.64) EPS, FY2018 earnings at ($0.65) EPS, FY2019 earnings at $0.30 EPS, FY2021 earnings at $1.62 EPS and FY2022 earnings at $2.64 EPS.
A number of other brokerages have also recently commented on COLL. Janney Montgomery Scott set a $26.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, February 6th. Piper Jaffray Companies set a $33.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Monday, November 13th. Needham & Company LLC raised their target price on Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $27.17.
A number of institutional investors have recently modified their holdings of the business. Nationwide Fund Advisors grew its holdings in Collegium Pharmaceutical by 27.8% during the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after acquiring an additional 2,802 shares during the period. Royal Bank of Canada grew its holdings in Collegium Pharmaceutical by 12.7% during the 2nd quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock worth $365,000 after acquiring an additional 3,285 shares during the period. Benjamin F. Edwards & Company Inc. grew its holdings in Collegium Pharmaceutical by 87.5% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock worth $138,000 after acquiring an additional 3,500 shares during the period. Teton Advisors Inc. grew its holdings in Collegium Pharmaceutical by 18.5% during the 4th quarter. Teton Advisors Inc. now owns 32,000 shares of the specialty pharmaceutical company’s stock worth $591,000 after acquiring an additional 5,000 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Collegium Pharmaceutical by 12.8% during the 3rd quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock worth $475,000 after acquiring an additional 5,136 shares during the period. Hedge funds and other institutional investors own 82.40% of the company’s stock.
In related news, CTO Alison B. Fleming sold 4,029 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $17.00, for a total transaction of $68,493.00. Following the completion of the transaction, the chief technology officer now directly owns 28,513 shares of the company’s stock, valued at approximately $484,721. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Alison B. Fleming sold 4,601 shares of the firm’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total value of $79,367.25. Following the transaction, the insider now directly owns 28,513 shares of the company’s stock, valued at $491,849.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,055,558 shares of company stock valued at $18,570,177. 25.76% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Analysts Offer Predictions for Collegium Pharmaceutical Inc’s FY2017 Earnings (COLL)” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/14/analysts-offer-predictions-for-collegium-pharmaceutical-incs-fy2017-earnings-coll.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.